" class="no-js "lang="en-US"> Aracari Biosciences - Medtech Alert
Friday, June 20, 2025
Aracari Biosciences | Pharmtech Focus

Aracari Biosciences

About Aracari Biosciences

Aracari Biosciences

Drug discovery remains an expensive and time-consuming process. Promising compounds proceed through clinical trials only to have many fail before FDA approval. Aracari Biosciences aims to simplify this process by more accurately and efficiently evaluating promising drug compounds in a human tissue-on-a-chip model prior to clinical trials. Our​ proprietary, Vascularized Micro-Organ (VMO) platform is the first to contain a 3D, perfused network of living, dynamic human blood vessels that deliver nutrients and drugs directly to tissues just as in the body. Ask about our oncology models that incorporate multiple human tumor types within the vascularized tissue or our blood-brain barrier model for testing trans-barrier transport of drug compounds targeting the brain.

Related Story

National Institute of Health (NIH) Awards Aracari Biosciences a Grant to Further Develop Proprietary Human Bone Marrow Technology That Models in Vivo Drug Responses

May 6 2022

Aracari Biosciences, Inc. announces a grant award from the National Institute of Health (NIH) to […]